Published in:
Open Access
01-12-2014 | Research article
The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis
Authors:
Edward Fox, Barbara Green, Clyde Markowitz, Ronald Murray, Andrew D Goodman, Stephen J Glenski, Pippa Loupe, Jo Nita Cogburn
Published in:
BMC Neurology
|
Issue 1/2014
Login to get access
Abstract
Background
Many patients with relapsing-remitting multiple sclerosis (MS) treated with high-dose interferon-β (IFNβ) develop serum binding antibodies (BAb) and neutralizing antibodies (NAb). NAb reduces the biological activity of IFNβ, which contributes to clinical failure in these patients. We investigated whether access to antibody (Ab) test results would alter usual care of (IFNβ)-treated patients and whether BAb could predict NAb.
Methods
This was a randomized, controlled, open-label, parallel-group, multicenter study in patients with multiple sclerosis. Subjects (n = 1358) were randomly assigned to Ab testing or usual care. BAb and NAb titres were measured using standard assays. Primary and secondary outcomes were the proportion of patients whose IFNβ therapy changed and the type of and reasons for therapy changes.
Results
Therapy changes differed between the Ab testing and usual care arms (19.6% and 14.0%, respectively; p = 0 · 004). Results from Ab testing were more frequently reported as the reason for therapy change in the Ab testing arm than in the usual care arm (p < 0.0001). NAb and BAb positivity significantly increased the likelihood of therapy change and reduced IFNβ-associated adverse events. BAb titres were a significant predictor of NAb positivity (p = 0.0012). Initial BAb-positive and NAb-positive status in both study arms had a significant impact on the overall number of patients with a therapy change (p < 0.05).
Conclusion
Access to Ab test results impacted therapy management. BAb titres can predict NAb positivity in patients on high-dose IFNβ.